ipilimumab
bms
['ligand']
dr. shared autographed dr. steve o day abstract 2010; later said, paraphrased i won t engage in a street fight about whether it s better to block receptors or ligands in cancer immunotherapy as he described pd1/pd-l1 that followed success of ipilumumab #asco22 
Physician-Scientist; Translational Oncologist https://t.co/8RMRruPhfx Director @BrownUCancer Associate Dean @BrownMedicine